Metabolic Hallmarks of Metastasis Formation

Trends in Cell Biology

Volumn 28, Issue 8, 2018, Pages 673-684

  Elia, Ilaria ^a,b   Doglioni, Ginevra ^a,b   Fendt, Sarah Maria ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b Katholieke Universiteit   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADENOSINE TRIPHOSPHATE; ESTROGEN RELATED RECEPTOR ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCARBOXYLATE TRANSPORTER 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE;

AMINO ACID METABOLISM; ANTIOXIDANT ACTIVITY; CANCER CELL; CANCER GROWTH; CANCER LOCALIZATION; CELL METABOLISM; CELL SURVIVAL; CIRCULATING TUMOR CELL; EXTRACELLULAR MATRIX; FATTY ACID METABOLISM; GLUCOSE METABOLISM; GLYCOLYSIS; HOMEOSTASIS; HUMAN; METABOLIC PARAMETERS; METASTASIS; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR INVASION; ANIMAL; METABOLISM; NEOPLASM; PATHOLOGY;

ADENOSINE TRIPHOSPHATE; ANIMALS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS;

EID: 85046740404     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2018.04.002     Document Type: Review

References (93)

1. Elia, I., et al. Organ-specific cancer metabolism and its potential for therapy. Handb. Exp. Pharmacol. 233 (2016), 321–353.
2. Ferlay, J., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136 (2015), E359–E386.
3. Massagué J., Obenauf, A.C., Metastatic colonization by circulating tumour cells. Nature, 529, 2016, 298.
4. Peinado, H., et al. Pre-metastatic niches: organ-specific homes for metastases. Nat. Rev. Cancer 17 (2017), 302–317.
5. Peinado, H., et al. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin. Cancer Biol. 21 (2011), 139–146.
6. Lunt, S.Y., Fendt, S.M., Metabolism – a cornerstone of cancer initiation, progression, immune evasion and treatment response. Curr. Opin. Syst. Biol. 8 (2018), 67–72.
7. Payen, V.L., et al. Metabolic changes associated with tumor metastasis, part 1: tumor pH, glycolysis and the pentose phosphate pathway. Cell. Mol. Life Sci. 73 (2016), 1333–1348.
8. Lehuédé C., et al. Metabolic plasticity as a determinant of tumor growth and metastasis. Cancer Res., 76, 2016, 5201.
9. Schild, T., et al. Unique metabolic adaptations dictate distal organ-specific metastatic colonization. Cancer Cell 33 (2018), 347–354.
10. Teoh, S.T., Lunt, S.Y., Metabolism in cancer metastasis: bioenergetics, biosynthesis, and beyond. Wiley Interdiscip. Rev. Syst. Biol. Med., 10, 2018, e1406.
11. Fendt, S.M., Is there a therapeutic window for metabolism-based cancer therapies?. Front. Endocrinol., 8, 2017, 150.
12. Walsh, C.T., et al. Eight kinetically stable but thermodynamically activated molecules that power cell metabolism. Chem. Rev. 118 (2017), 1460–1494.
13. Lunt, S.Y., Vander Heiden, M.G., Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Ann. Rev. Cell Dev. Biol. 27 (2011), 441–464.
14. Lorendeau, D., et al. Metabolic control of signaling pathways and metabolic auto-regulation. Biol. Cell 107 (2015), 251–272.
15. Rinaldi, G., et al. Metabolic interactions in cancer: cellular metabolism at the interface between the microenvironment, the cancer cell phenotype and the epigenetic landscape. Wiley Interdiscip. Rev. Syst. Biol. Med., 10, 2017, e1397.
16. Mo, P., Yang, S., PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Front. Biosci. 23 (2018), 1241–1256.
17. Lunt, S., et al. Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation. Mol. Cell 57 (2015), 95–107.
18. EdryBotzer, L., et al. Hexokinase 2 is a determinant of neuroblastoma metastasis. Br. J. Cancer 114 (2016), 759–766.
19. Anderson, M., et al. Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer. Oncotarget 8 (2016), 56081–56094.
20. Sun, H., et al. Knockdown of PKM2 suppresses tumor growth and invasion in lung adenocarcinoma. Int. J. Mol. Sci. 16 (2015), 24574–24587.
21. Liu, W.R., et al. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma. Oncotarget 6 (2015), 846–861.
22. Lu, W., et al. Up-regulation of PKM2 promote malignancy and related to adverse prognostic risk factor in human gallbladder cancer. Sci. Rep., 6, 2016, 26351.
23. Yu, G., et al. PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma. Mol. Cancer, 14, 2015, 193.
24. Zhou, C.F., et al. Pyruvate kinase type M2 is upregulated in colorectal cancer and promotes proliferation and migration of colon cancer cells. IUBMB Life 64 (2012), 775–782.
25. Nokin, M.J., et al. Methylglyoxal, a glycolysis side-product, induces Hsp90 glycation and YAP-mediated tumor growth and metastasis. eLife, 5, 2016, e19375.
26. Lei, Q.Y., et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol. Cell. Biol. 28 (2008), 2426–2436.
27. Overholtzer, M., et al. Transforming properties of YAP a candidate oncogene on the chromosome 11q22 amplicon. Proc. Natl. Acad. Sci. U. S. A., 103, 2006, 12405.
28. Bonuccelli, G., et al. Ketones and lactate “fuel” tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 9 (2010), 3506–3514.
29. Payen, V.L., et al. Monocarboxylate transporter MCT1 promotes tumor metastasis independently of its activity as a lactate transporter. Cancer Res., 77, 2017, 5591.
30. Porporato, P.E., et al. A mitochondrial switch promotes tumor metastasis. Cell Rep. 8 (2014), 754–766.
31. Torrano, V., et al. The metabolic co-regulator PGC1[alpha] suppresses prostate cancer metastasis. Nat. Cell Biol. 18 (2016), 645–656.
32. LeBleu, V.S., et al. PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat. Cell Biol. 16 (2014), 992–1003.
33. Samanta, D., et al. PHGDH expression is required for mitochondrial redoxhomeostasis, breast cancer stem cell maintenance, and lung metastasis. Cancer Res., 76, 2016, 4430.
34. Luo, C., et al. A PGC1α-mediated transcriptional axis suppresses melanoma metastasis. Nature, 537, 2016, 422.
35. Yang, L., et al. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol. Syst. Biol., 10, 2014, 728.
36. Rodrigues, M.F., et al. Enhanced OXPHOS, glutaminolysis and β-oxidation constitute the metastatic phenotype of melanoma cells. Biochem. J. 473 (2016), 703–715.
37. Camarda, R., et al. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat. Med., 22, 2016, 427.
38. Kuntz, E.M., et al. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nat. Med., 23, 2017, 1234.
39. Dornier, E., et al. Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. Nat. Commun., 8, 2017, 2255.
40. Knott, S.R.V., et al. Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554 (2018), 378–381.
41. Sounni, N.E., et al. Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal. Cell Metab. 20 (2014), 280–294.
42. Antalis, C.J., et al. Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification. Clin. Exp. Metastasis 28 (2011), 733–741.
43. Nath, A., et al. Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma. Sci. Rep., 5, 2015, 14752.
44. Nath, A., Chan, C., Genetic alterations in fatty acid transport and metabolism genes are associated with metastatic progression and poor prognosis of human cancers. Sci. Rep., 6, 2016, 18669.
45. Keckesova, Z., et al. LACTB is a tumour suppressor that modulates lipid metabolism and cell state. Nature, 543, 2017, 681.
46. Li, J., et al. Lipid desaturation is a metabolic marker and therapeutic target of ovarian cancer stem cells. Cell Stem Cell 20 (2017), 303–314.e305.
47. Rios Garcia, M., et al. Acetyl-CoA carboxylase 1-dependent protein acetylation controls breast cancer metastasis and recurrence. Cell Metab. 26 (2017), 842–855.e845.
48. Schug, Z.T., et al. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell 27 (2015), 57–71.
49. Comerford, S.A., et al. Acetate dependence of tumors. Cell 159 (2014), 1591–1602.
50. Sun, L., et al. Decreased expression of acetyl-CoA synthase 2 promotes metastasis and predicts poor prognosis in hepatocellular carcinoma. Cancer Sci. 108 (2017), 1338–1346.
51. Shi, X., et al. The abundance of metabolites related to protein methylation correlates with the met1astatic capacity of human melanoma xenografts. Sci. Adv., 3, 2017, eaao5268.
52. 2+ mammary cancer. Nature, 553, 2016, 366.
53. Hosseini, H., et al. Early dissemination seeds metastasis in breast cancer. Nature, 2016, 10.1038/nature20785 Published online December 14, 2016.
54. Hawk, M.A., Schafer, Z.T., Mechanisms of redox metabolism and cancer cell survival during extracellular matrix detachment. J. Biol. Chem., 2018, 10.1074/jbc.TM117.000260 Published online January 16, 2018.
55. Dey, S., et al. ATF4-dependent induction of heme oxygenase 1 prevents anoikis and promotes metastasis. J. Clin. Invest. 125 (2015), 2592–2608.
56. Fang, J., et al. Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. Int. J. Cancer 109 (2004), 1–8.
57. Baldelli, S., et al. PGC-1α buffers ROS-mediated removal of mitochondria during myogenesis. Cell Death Dis., 5, 2014, e1515.
58. Schafer, Z.T., et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461 (2009), 109–113.
59. Kamarajugadda, S., et al. Glucose oxidation modulates anoikis and tumor metastasis. Mol. Cell. Biol. 32 (2012), 1893–1907.
60. Schell, J.C., et al. A role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growth. Mol. Cell 56 (2014), 400–413.
61. Fendt, S.M., et al. Reductive glutamine metabolism is a function of the alpha-ketoglutarate to citrate ratio in cells. Nat. Commun., 4, 2013, 2236.
62. Fendt, S.M., et al. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res. 73 (2013), 4429–4438.
63. Metallo, C.M., et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481 (2012), 380–384.
64. Mullen, A.R., et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481 (2012), 385–388.
65. Jiang, L., et al. Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature 532 (2016), 255–258.
66. Piskounova, E., et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 527 (2015), 186–191.
67. Le Gal, K., et al. Antioxidants can increase melanoma metastasis in mice. Sci. Transl. Med., 7, 2015, 308re308.
68. Monteiro, J., Fodde, R., Cancer stemness and metastasis: therapeutic consequences and perspectives. Eur. J. Cancer 46 (2010), 1198–1203.
69. Elia, I., et al. Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat. Commun., 8, 2017, 15267.
70. Dong, C., et al. Loss of FBP1 by snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell 23 (2013), 316–331.
71. Pascual, G., et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature 541 (2017), 41–45.
72. Weitz, J., et al. Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin. Cancer Res., 4, 1998, 343.
73. Gall, T.H., et al. Reduced dissemination of circulating tumor cells with no-touch isolation surgical technique in patients with pancreatic cancer. JAMA Surg. 149 (2014), 482–485.
74. Yamashita, J.I., et al. Detection of circulating tumor cells in patients with non–small cell lung cancer undergoing lobectomy by video-assisted thoracic surgery: a potential hazard for intraoperative hematogenous tumor cell dissemination. J. Thorac. Cardiovasc. Surg. 119 (2000), 899–905.
75. Liu, Y., Cao, X., Characteristics and significance of the pre-metastatic niche. Cancer Cell 30 (2016), 668–681.
76. Fong, M.Y., et al. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat. Cell Biol. 17 (2015), 183–194.
77. Andrzejewski, S., et al. PGC-1α promotes breast cancer metastasis and confers bioenergetic flexibility against metabolic drugs. Cell Metab. 26 (2017), 778–787.e5.
78. Loo, J.M., et al. Extracellular metabolic energetics can promote cancer progression. Cell 160 (2015), 393–406.
79. Dupuy, F., et al. PDK1-dependent metabolic reprogramming dictates metastatic potential in breast cancer. Cell Metab. 22 (2015), 577–589.
80. Gaude, E., Frezza, C., Tissue-specific and convergent metabolic transformation of cancer correlates with metastatic potential and patient survival. Nat. Commun., 7, 2016, 13041.
81. Tseng, C.W., et al. Transketolase regulates the metabolic switch to control breast cancer cell metastasis via the alpha-ketoglutarate signaling pathway. Cancer Res., 2018, 10.1158/0008-5472.CAN-17-2906 Published online March 29, 2018.
82. Elia, I., Fendt, S.M., In vivo cancer metabolism is defined by the nutrient microenvironment. Transl. Cancer Res. 5 (2016), S1284–S1287.
83. Davidson, S.M., et al. Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer. Cell Metab. 23 (2016), 517–528.
84. Hensley, C.T., et al. Metabolic heterogeneity in human lung tumors. Cell 164 (2016), 681–694.
85. Christen, S., et al. Breast cancer-derived lung metastases show increased pyruvate carboxylase-dependent anaplerosis. Cell Rep. 17 (2016), 837–848.
86. Mashimo, T., et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 159 (2014), 1603–1614.
87. 13 C]glucose in human brain tumors in vivo. NMR Biomed. 25 (2012), 1234–1244.
88. Chen, J., et al. Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain. Cancer Res. 75 (2015), 554–565.
89. Chen, E.I., et al. Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res., 67, 2007, 1472.
90. Kim, H.M., et al. Site-specific metabolic phenotypes in metastatic breast cancer. J. Transl. Med., 12, 2014, 354.
91. Cha, Y.J., et al. Differential site-based expression of pentose phosphate pathway-related proteins among breast cancer metastases. Dis. Markers, 2017, 2017, 7062517.
92. McDonald, O.G., et al. Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis. Nat. Genet. 49 (2017), 367–376.
93. DeVita, V.T., Chu, E., A history of cancer chemotherapy. Cancer Res., 68, 2008, 8643.